GlassScriptPhysician profile
Amanda Nicole Britt
NPI 1649436569
$1,358.16
in general payments reported to CMS, 2019-2025
27 companies · $405 in 2025
The $405 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.13 · 2020: $52.23 · 2021: $123 · 2022: $185 · 2023: $205 · 2024: $358 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $433.48 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $111.13 | 2023-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $85.52 | 2022 | |
| Novo Nordisk INC | $76.98 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.64 | 2024-2025 | Caplyta |
| Abbvie INC. | $61.12 | 2023-2025 | Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $47.61 | 2021-2025 | |
| Pfizer INC. | $45.95 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $40.15 | 2022-2023 | Quviviq |
| Ucb, INC. | $38.44 | 2025 | Briviact |
| Medtronic, INC. | $34.26 | 2024-2025 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.21 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $32.00 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $27.83 | 2021-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $26.67 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.71 | 2023 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $19.51 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $17.77 | 2025 | Neffy |
| Collegium Pharmaceutical, INC. | $17.67 | 2025 | Jornay Pm |
| Dexcom, INC. | $16.60 | 2023 | Dexcom G6 Transmitter |
| Axonics, INC. | $16.26 | 2021 | |
| Astellas Pharma US INC | $15.72 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.86 | 2021 | |
| Genentech USA, INC. | $14.33 | 2020 | |
| Abbott Laboratories | $13.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.12 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Britt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.